The Comprehensive Systematic Review of Use of Prostaglandin Analogues in Glaucoma Treatment
Keywords:
Prostaglandin Analogues, Glaucoma, Intraocular Pressure, Bimatoprost, Latanoprost, Travoprost, Systematic ReviewAbstract
Introduction: Glaucoma is a leading cause of irreversible blindness worldwide, characterized by progressive optic neuropathy, with elevated intraocular pressure (IOP) being the primary modifiable risk factor. Prostaglandin analogues (PGAs) have emerged as a cornerstone of pharmacological therapy due to their potent IOP-lowering efficacy and once-daily dosing (Aptel, Cucherat & Denis, 2008). This systematic review synthesizes evidence on the efficacy, safety, and clinical utility of PGAs in glaucoma management.
Methods: A systematic literature review was conducted. We screened studies based on predefined criteria, including human studies on adult glaucoma patients, evaluation of PGA interventions, reporting of clinical outcomes (IOP reduction, visual field, adverse events), and acceptable study designs (RCTs, cohort studies, systematic reviews, etc.). Data from 80 included sources were extracted concerning study design, patient population, interventions, IOP efficacy, safety profiles, and key conclusions.
Results: PGAs consistently demonstrated substantial IOP reduction, with bimatoprost often showing numerically superior efficacy (mean reduction up to 9.16 mmHg, 35.2%) compared to latanoprost (7.7 mmHg, 31%) and travoprost (8.0-8.9 mmHg) (Brandt et al., 2001; Hedman & Alm, 2000). The United Kingdom Glaucoma Treatment Study (UKGTS) provided pivotal evidence that latanoprost significantly reduces the risk of visual field deterioration compared to placebo (Hazard Ratio 0.44) (Garway-Heath et al., 2015). Safety profiles varied, with bimatoprost associated with the highest incidence of conjunctival hyperemia, while latanoprost was generally better tolerated (Aptel, Cucherat & Denis, 2008). Novel formulations like latanoprostene bunod and preservative-free PGAs offered enhanced efficacy or improved tolerability (Weinreb et al., 2017; Hommer et al., 2010).
Discussion: The analysis reveals a critical trade-off between the maximal IOP-lowering potential of bimatoprost and the superior tolerability of latanoprost. Long-term efficacy is maintained, and PGAs are effective in special populations like normal-tension and angle-closure glaucoma. Preservative-free formulations address ocular surface disease concerns, potentially improving adherence.
Conclusion: Prostaglandin analogues remain the first-line pharmacological treatment for glaucoma, offering effective and sustained IOP reduction. Clinical choice should individualize therapy based on the required IOP target, patient tolerance, and ocular surface health. Future research should focus on long-term comparative outcomes, personalized medicine approaches, and novel drug delivery systems.
References
A. Alm, and I. Widengård. “Latanoprost: Experience of 2-Year Treatment in Scandinavia.” Acta Ophthalmologica, 2000.
A. Chabi, R. Varma, J. Tsai, R. Lupinacci, J. Pigeon, C. Baranak, L. Noble, C. Lines, and T. Ho. “Randomized Clinical Trial of the Efficacy and Safety of Preservative-Free Tafluprost and Timolol in Patients with Open-Angle Glaucoma or Ocular Hypertension.” American Journal of Ophthalmology-Glaucoma, 2012.
A. Hommer, and F. Kimmich. “Switching Patients from Preserved Prostaglandin-Analog Monotherapy to Preservative-Free Tafluprost.” Clinical Ophthalmology, 2011.
A. Hommer, Osman Mohammed Ramez, M. Burchert, and F. Kimmich. “IOP-Lowering Efficacy and Tolerability of Preservative-Free Tafluprost 0.0015% Among Patients with Ocular Hypertension or Glaucoma.” Current Medical Research and Opinion, 2010.
A. Penman, K. W. Crowder, and W. Watkins. “Latanoprost for Open-Angle Glaucoma,” 2020.
B. Friström. “A 6-Month, Randomized, Double-Masked Comparison of Latanoprost with Timolol in Patients with Open Angle Glaucoma or Ocular Hypertension.” Acta Ophthalmologica, 2009.
C. Hirsch. “In Open-Angle Glaucoma, Latanoprost Improved Visual Field Preservation.” Annals of Internal Medicine, 2015.
C. Kara, E. Sen, Kadriye Ufuk Elgin, Kurtuluş Serdar, and P. Yılmazbaş. “Does the Intraocular Pressure-Lowering Effect of Prostaglandin Analogues Continue over the Long Term?” International Ophtalmology, 2017.
C. Traverso, A. Ropo, M. Papadia, and H. Uusitalo. “A Phase II Study on the Duration and Stability of the Intraocular Pressure-Lowering Effect and Tolerability of Tafluprost Compared With Latanoprost.” Journal of Ocular Pharmacology and Therapeutics, 2010.
C. Webers, H. Beckers, M. Zeegers, R. Nuijts, F. Hendrikse, and J. Schouten. “The Intraocular Pressure-Lowering Effect of Prostaglandin Analogs Combined with Topical β-Blocker Therapy: A Systematic Review and Meta-Analysis.” Ophthalmology (Rochester, Minn.), 2010.
Cory Swymer, and Michael W. Neville. “Tafluprost: The First Preservative-Free Prostaglandin to Treat Open-Angle Glaucoma and Ocular Hypertension.” The Annals of Pharmacotherapy, 2012.
Cw Lee, F. Buckley, S. Costello, and Steven Kelly. “A Systematic Review of the Characteristics of Randomised Control Trials Featuring Prostaglandins for the Treatment of Glaucoma*.” Current Medical Research and Opinion, 2008.
D. Garway-Heath, D. Crabb, C. Bunce, G. Lascaratos, F. Amalfitano, N. Anand, A. Azuara-Blanco, et al. “Latanoprost for Open-Angle Glaucoma (UKGTS): A Randomised, Multicentre, Placebo-Controlled Trial.” The Lancet, 2015.
———, et al. “Latanoprost Treatment for Open Angle Glaucoma. The United Kingdom Glaucoma Treatment Study: A Multicentre, Randomised, Placebo-Controlled Clinical Trial,” 2015.
E. Maul, F. G. Carrasco, V. P. Costa, J. Casiraghi, E. Vargas, J. S. Sarmina, and R. Mayol. “A 6-Week, Multicenter, Randomized, Double-Masked, Parallel-Group Study Comparing Travoprost 0.004% to Latanoprost 0.005% Followed by 6-Week, Open-Label Treatment with Travoprost 0.004%.” Clinical Therapeutics, 2007.
E. O'Donoghue. “A Comparison of Latanoprost and Dorzolamide in Patients with Glaucoma and Ocular Hypertension: A 3 Month, Randomised Study.” British Journal of Ophthalmology, 2000.
E. S. Arcieri, A. Santana, F. N. Rocha, G. L. Guapo, and V. P. Costa. “Blood-Aqueous Barrier Changes After the Use of Prostaglandin Analogues in Patients with Pseudophakia and Aphakia: A 6-Month Randomized Trial.” A M A Archives of Ophthalmology, 2005.
Ece Turan-Vural, Banu Torun-Acar, and S. Acar. “Effect of Ketorolac Add-On Treatment on Intra-Ocular Pressure in Glaucoma Patients Receiving Prostaglandin Analogues.” Ophthalmologica, 2011.
F. Aptel, M. Cucherat, and P. Denis. “Efficacy and Tolerability of Prostaglandin Analogs: A Meta-Analysis of Randomized Controlled Clinical Trials.” Journal of Glaucoma, 2008.
F. Aptel, and P. Denis. “Balancing Efficacy and Tolerability of Prostaglandin Analogues and Prostaglandin–Timolol Fixed Combinations in Primary Open-Angle Glaucoma.” Current Medical Research and Opinion, 2011.
F. Topouzis, S. Melamed, H. Danesh-Meyer, A. P. Wells, V. Kozobolis, H. Wieland, R. Andrew, et al. “A 1-Year Study to Compare the Efficacy and Safety of Once-Daily Travoprost 0.004%/Timolol 0.5% to Once-Daily Latanoprost 0.005%/Timolol 0.5% in Patients with Open-Angle Glaucoma or Ocular Hypertension.” European Journal of Ophthalmology, 2007.
Fidya Ainun Tikha, and Aditia Rizka Rahadi. “Prostaglandin Analogs Regimen for Open-Angle Glaucoma or Hypertensive Ocular, Is It Still Effective Nowadays?: A Systematic Review.” Ophthalmologica Indonesiana, 2024.
G. Lascaratos, D. Garway-Heath, Robyn Burton, C. Bunce, W. Xing, D. Crabb, Richard A. Russell, and Ameet Shah. “The United Kingdom Glaucoma Treatment Study: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial: Baseline Characteristics.” Ophthalmology (Rochester, Minn.), 2013.
Gary C. Brown, and Melissa M. Brown. “Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma.” Journal of Ocular Pharmacology and Therapeutics, 2019.
Gentian Hoxha, K. Spahiu, Gazmend Kaçaniku, Fëllanza Ismajli-Hoxha, and M. Ismaili. “Comparison of Prostaglandin Analogue, Beta-Blockers and Prostaglandin Analogue/Beta-Blockers Fixed Combination in Patients with Primary Open-Angle Glaucoma.” Spektrum Der Augenheilkunde, 2013.
H. Lou, Hao Wang, Ying Zong, Jin-wei Cheng, and R. Wei. “Efficacy and Tolerability of Prostaglandin–Timolol Fixed Combinations: An Updated Systematic Review and Meta-Analysis.” Current Medical Research and Opinion, 2015.
I. Goldberg, J. Cunha-Vaz, J. Jakobsen, J. Nordmann, Elisabeth Trost, and E. Sullivan. “Comparison of Topical Travoprost Eye Drops Given Once Daily and Timolol 0.5% Given Twice Daily in Patients with Open-Angle Glaucoma or Ocular Hypertension.” Journal of Glaucoma, 2001.
J. A. Tumbocon, and Anne Marie Macasaet. “Efficacy and Safety of Tafluprost 0.0015% – Retrospective Analysis of Real-World Data from the Philippines.” Clinical Ophthalmology, 2019.
J. Brandt, A. Vandenburgh, Kuankuan Chen, and S. Whitcup. “Comparison of Once-or Twice-Daily Bimatoprost with Twice-Daily Timolol in Patients with Elevated IOP,” 2001.
Jieting Peng, Wenrui Huang, and Junguo Duan. “Efficacy and Safety of Prostaglandin Drugs for Elevated Intraocular Pressure: A Bayesian Network Meta-Analysis.” Frontiers in Medicine, 2025.
Jin-wei Cheng, Ji-ping Cai, and R. Wei. “Meta-Analysis of Medical Intervention for Normal Tension Glaucoma.” Ophthalmology (Rochester, Minn.), 2009.
Jin-wei Cheng, Ji-ping Cai, You Li, and R. Wei. “A Meta-Analysis of Topical Prostaglandin Analogs in the Treatment of Chronic Angle-Closure Glaucoma.” Journal of Glaucoma, 2009.
K. Kawase, J. Vittitow, R. Weinreb, M. Araie, Shigeru Setsuko Miki Kiyoshi Kazuhide Takuji Yasuaki Tomoy Hoshiai Hashida Iwasaki Kano Kawase Kato Kuwayama, Shigeru Hoshiai, Setsuko Hashida, et al. “Long-Term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.” Advances in Therapy, 2016.
Kang-Jung Lo, Y. Ko, De-Kuang Hwang, and C. J. Liu. “The Influence of Topical Non-Steroidal Anti-Inflammatory Drugs on the Intraocular Pressure Lowering Effect of Topical Prostaglandin Analogues—A Systemic Review and Meta-Analysis.” PLoS ONE, 2020.
Katarina Hedman, and Albert Alm. “A Pooled-Data Analysis of Three Randomized, Double-Masked, Six-Month Clinical Studies Comparing the Intraocular Pressure Reducing Effect of Latanoprost and Timolol.” European Journal of Ophthalmology, 2000.
Kenji Inoue, K. Ishida, and G. Tomita. “Effectiveness and Safety of Switching from Prostaglandin Analog Monotherapy to Prostaglandin/Timolol Fixed Combination Therapy or Adding Ripasudil.” Japanese Journal of Ophthalmology, 2018.
Kenji Inoue, K. Ishida, G. Tomita, and H. Noma. “A Scoping Review and Network Meta-Analysis for Efficacy and Safety of Glaucoma Medication in Japanese Patients.” Japanese Journal of Ophthalmology, 2020.
L. Quaranta, E. Biagioli, I. Riva, E. Rulli, D. Poli, A. Katsanos, and I. Floriani. “Prostaglandin Analogs and Timolol-Fixed Versus Unfixed Combinations or Monotherapy for Open-Angle Glaucoma: A Systematic Review and Meta-Analysis.” Journal of Ocular Pharmacology and Therapeutics, 2013.
Liang Lin, Y. Zhao, P. Chew, C. Sng, H. Wong, L. Yip, T. S. Wu, et al. “Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension.” The Annals of Pharmacotherapy, 2014.
M. Ayala, and E. Chen. “The Influence of Topical Prostaglandin Analogues in Inflammation After Selective Laser Trabeculoplasty Treatment.” Journal of Ocular Pharmacology and Therapeutics, 2012.
M. Cellini, R. Caramazza, D. Bonsanto, B. Bernabini, and Emilio C. Campos. “Prostaglandin Analogs and Blood-Aqueous Barrier Integrity: A Flare Cell Meter Study.” Ophthalmologica, 2004.
M. Cucherat, I. Stalmans, and J. Rouland. “Relative Efficacy and Safety of Preservative-Free Latanoprost (T2345) for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: An Adjusted Indirect Comparison Meta-Analysis of Randomized Clinical Trials.” Journal of Glaucoma, 2014.
M. Orme, S. Collins, H. Dakin, S. Kelly, and J. Loftus. “Mixed Treatment Comparison and Meta-Regression of the Efficacy and Safety of Prostaglandin Analogues and Comparators for Primary Open-Angle Glaucoma and Ocular Hypertension.” Current Medical Research and Opinion, 2010.
M. Sanford. “Preservative-Free Latanoprost Eye Drops in Patients with Primary Open-Angle Glaucoma/Ocular Hypertension.” Clinical Drug Investigation, 2014.
M. Vetrugno, N. Cardascia, F. Cantatore, and C. Sborgia. “Comparison of the Effects of Bimatoprost and Timolol on Intraocular Pressure and Pulsatile Ocular Blood Flow in Patients with Primary Open-Angle Glaucoma: A Prospective, Open-Label, Randomized, Two-Arm, Parallel-Group Study.” Current Therapeutic Research, 2004.
Myoung-Hee Park, Kyong-Hwan Cho, and J. Moon. “The Effects of Prostaglandin Analogues on the Corneal Thickness,” 2009.
N. Cardascia, M. Vetrugno, T. Trabucco, F. Cantatore, and C. Sborgia. “Effects of Travoprost Eye Drops on Intraocular Pressure and Pulsatile Ocular Blood Flow: A 180-Day, Randomized, Double-Masked Comparison with Latanoprost Eye Drops in Patients with Open-Angle Glaucoma.” Current Therapeutic Research, 2003.
N. Markomichelakis, A. Kostakou, I. Halkiadakis, Sonia Chalkidou, D. Papakonstantinou, and G. Georgopoulos. “Efficacy and Safety of Latanoprost in Eyes with Uveitic Glaucoma.” Graefe's Archive for Clinical and Experimental Ophthalmology, 2009.
N. Orzalesi, L. Rossetti, A. Bottoli, and P. Fogagnolo. “Comparison of the Effects of Latanoprost, Travoprost, and Bimatoprost on Circadian Intraocular Pressure in Patients with Glaucoma or Ocular Hypertension.” Ophthalmology (Rochester, Minn.), 2006.
N. Tamçelik, B. Izgi, A. Temel, N. Yıldırım, M. Okka, A. Özcan, N. Yüksel, U. Elgin, Ç. Altan, and Baris Ozer. “Prospective, Non-Interventional, Multicenter Study of the Intraocular Pressure-Lowering Effects of Prostaglandin Analog/Prostamide-Containing Therapies in Previously Treated Patients with Open-Angle Glaucoma or Ocular Hypertension.” Clinical Ophthalmology, 2017.
N. Yıldırım, A. Şahin, and Saadet Gultekin. “The Effect of Latanoprost, Bimatoprost, and Travoprost on Circadian Variation of Intraocular Pressure in Patients With Open-Angle Glaucoma.” Journal of Glaucoma, 2008.
Ni Li, Xiaoming Chen, Yong Zhou, Mao-ling Wei, and Xun Yao. “Travoprost Compared with Other Prostaglandin Analogues or Timolol in Patients with Open‐angle Glaucoma or Ocular Hypertension: Meta‐analysis of Randomized Controlled Trials.” Clinical and Experimental Ophthalmology, 2006.
Nikhil Sharma, M. N. Khatib, A. Balaraman, Roopashree R, Mandeep Kaur, Manish Srivastava, Amit Barwal, et al. “Intracameral Prostaglandin Implant Vs Timolol in Open-Angle Glaucoma or Ocular Hypertension: A Systematic Review and Meta-Analysis.” AJO International, 2025.
O. Koz, A. Ozsoy, A. Yarangumeli, S. Kenan Kose, and G. Kural. “Comparison of the Effects of Travoprost, Latanoprost and Bimatoprost on Ocular Circulation: A 6-Month Clinical Trial.” Acta Ophthalmologica, 2007.
P. Denis, A. Lafuma, B. Khoshnood, V. Mimaud, and G. Berdeaux. “A Meta-Analysis of Topical Prostaglandin Analogues Intra-Ocular Pressure Lowering in Glaucoma Therapy.” Current Medical Research and Opinion, 2007.
P. Denis, C. Baudouin, A. Bron, J. Nordmann, J. Renard, J. Rouland, E. Sellem, and M. Amrane. “First-Line Latanoprost Therapy in Ocular Hypertension or Open-Angle Glaucoma Patients: A 3-Month Efficacy Analysis Stratified by Initial Intraocular Pressure.” BMC Ophthalmology, 2010.
P. Harasymowycz, C. Royer, A. Cui, M. Barbeau, K. Jobin-Gervais, K. Mathurin, J. Lachaine, and C. Beauchemin. “Short-Term Efficacy of Latanoprostene Bunod for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Systematic Literature Review and a Network Meta-Analysis.” British Journal of Ophthalmology, 2021.
Qëndresë Daka, and V. Trkulja. “Efficacy and Tolerability of Mono-Compound Topical Treatments for Reduction of Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: An Overview of Reviews.” Croatian Medical Journal, 2014.
R. Meda, Qianqian Wang, David Paoloni, P. Harasymowycz, and I. Brunette. “The Impact of Chronic Use of Prostaglandin Analogues on the Biomechanical Properties of the Cornea in Patients with Primary Open-Angle Glaucoma.” British Journal of Ophthalmology, 2016.
R. Parrish, P. Palmberg, and Wang-Pui Sheu. “A Comparison of Latanoprost, Bimatoprost, and Travoprost in Patients with Elevated Intraocular Pressure: A 12-Week, Randomized, Masked-Evaluator Multicenter Study.” American Journal of Ophthalmology-Glaucoma, 2003.
R. Reis, Lucia Cristina dos Santos, M. P. Vila, and L. Magacho. “Effects of Travoprost 0.004% Ophthalmic Solution, Six Weeks After Its Laminated Packaging Had Been Removed, in Primary Open-Angle Glaucoma: A Randomized, Controlled, Investigator-Blinded Study.” Clinical Therapeutics, 2004.
R. van der Valk, C. Webers, T. Lumley, F. Hendrikse, M. Prins, and J. Schouten. “A Network Meta-Analysis Combined Direct and Indirect Comparisons Between Glaucoma Drugs to Rank Effectiveness in Lowering Intraocular Pressure.” Journal of Clinical Epidemiology, 2009.
R. Weinreb, J. Liebmann, K. Martin, P. Kaufman, and J. Vittitow. “Latanoprostene Bunod 0.024% in Subjects With Open-Angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.” Journal of Glaucoma, 2017.
Rajani Kadri, A. Shetty, Devika Parameshwar, Ajay A Kudva, Asha Achar, and J. Shetty. “Effect of Prostaglandin Analogues on Central Corneal Thickness in Patients with Glaucoma: A Systematic Review and Meta-Analysis with Trial Sequential Analysis.” Indian Journal of Ophthalmology, 2022.
Rodolfo Mastropasqua, Vincenzo Fasanella, E. Pedrotti, M. Lanzini, S. Staso, L. Mastropasqua, and L. Agnifili. “Trans-Conjunctival Aqueous Humor Outflow in Glaucomatous Patients Treated with Prostaglandin Analogues: An in Vivo Confocal Microscopy Study.” Graefe's Archive for Clinical and Experimental Ophthalmology, 2014.
S. Kymes, C. Burk, T. Feinman, Julia M. Williams, and D. Hollander. “Demonstration of an Online Tool to Assist Managed Care Formulary Evidence-Based Decision Making: Meta-Analysis of Topical Prostaglandin Analog Efficacy.” Therapeutics and Clinical Risk Management, 2011.
S. Raber, J. Mandema, Hanbin Li, and D. Nickens. “A Model-Based Dose–Response Meta-Analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma.” Journal of Ocular Pharmacology and Therapeutics, 2015.
Shahenda Mohamed, Asmaa Gamal El-Deen, A. Abosaif, and N. El-Koussy. “Effects of Preservative-Free and Preservative Prostaglandin Analogs on Ocular Surface by Impression Cytology in Glaucoma Patients.” Journal of Recent Advances in Medicine, 2023.
Stefano Ranno, M. Sacchi, Cinzia Brancato, D. Gilardi, Andrea Lembo, and P. Nucci. “A Prospective Study Evaluating IOP Changes After Switching from a Therapy with Prostaglandin Eye Drops Containing Preservatives to Nonpreserved Tafluprost in Glaucoma Patients.” TheScientificWorldJournal, 2012.
T. R. Einarson, Natalie A. Kulin, David P. Tingey, and M. Iskedjian. “Meta-Analysis of the Effect of Latanoprost and Brimonidine on Intraocular Pressure in the Treatment of Glaucoma.” Clinical Therapeutics, 2000.
T. Zimmerman, S. Hahn, Laurie Gelb, H. Tan, and Elizabeth E. Kim. “The Impact of Ocular Adverse Effects in Patients Treated with Topical Prostaglandin Analogs: Changes in Prescription Patterns and Patient Persistence.” Journal of Ocular Pharmacology and Therapeutics, 2009.
Vlad Diaconita, M. Quinn, Dania Jamal, B. Dishan, Monali S. Malvankar-Mehta, and C. Hutnik. “Washout Duration of Prostaglandin Analogues: A Systematic Review and Meta-Analysis.” Journal of Ophthalmology, 2018.
W. C. Stewart, A. Konstas, B. Kruft, Heather M Mathis, and J. Stewart. “Meta-Analysis of 24-h Intraocular Pressure Fluctuation Studies and the Efficacy of Glaucoma Medicines.” Journal of Ocular Pharmacology and Therapeutics, 2010.
W. C. Stewart, A. Konstas, L. A. Nelson, and B. Kruft. “Meta-Analysis of 24-Hour Intraocular Pressure Studies Evaluating the Efficacy of Glaucoma Medicines.” Ophthalmology (Rochester, Minn.), 2008.
W. Peng, Xiao-Yan Zhong, and Minbin Yu. “[Meta-Analysis of Randomized Controlled Trials Comparing Selective Laser Trabeculoplasty with Prostaglandin Analogue in the Primary Treatment of Open-Angle Glaucoma or Ocular Hypertention].” [Zhonghua Yan Ke Za Zhi] Chinese Journal of Ophthalmology, 2014.
W. Scherer. “Effect of Topical Prostaglandin Analog Use on Outcome Following Selective Laser Trabeculoplasty.” Journal of Ocular Pharmacology and Therapeutics, 2006.
W. Sponsel, G. Paris, Y. Trigo, and M. Pena. “Comparative Effects of Latanoprost (Xalatan) and Unoprostone (Rescula) in Patients with Open-Angle Glaucoma and Suspected Glaucoma.” American Journal of Ophthalmology-Glaucoma, 2002.
Wenquan Tang, Feng Zhang, Ke Liu, and Xuanchu Duan. “Efficacy and Safety of Prostaglandin Analogues in Primary Open-Angle Glaucoma or Ocular Hypertension Patients.” Medicine, 2019.
William G. Hodge, Jean Lachaine, I. Steffensen, C. Murray, D. Barnes, V. Foerster, T. Ducruet, and A. Morrison. “The Efficacy and Harm of Prostaglandin Analogues for IOP Reduction in Glaucoma Patients Compared to Dorzolamide and Brimonidine: A Systematic Review.” British Journal of Ophthalmology, 2007.
Y. Kuwayama, and A. Nomura. “Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety.” Advances in Therapy, 2014.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Irene Sekarjati (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
